The mainstay treatment for EOC includes the use of a Platinum-based therapy combined with taxanes.
Taxanes such as Paclitaxel or Docetaxel are a class of anticancer agents that bind to and stabilize microtubules inhibiting the process of cell division.
Docetaxel has been shown to be as effective as Paclitaxel, but with less neuro toxicity when used as a first line treatment.
Platinum-based antineoplastic drugs like Cisplatin and Carboplatin cause crosslinking (binding together the strands) of the DNA, thus inhibiting the synthesis of new DNA in fast growing cancer cells.
Neoadjuvant Chemotherapy (NACT)
The majority of women with advanced EOC suffer from a recurrence of the disease.
A disease progressing within 6-12 months after the last dose of treatment is defined as platinum resistant. When this occurs, patients may receive a single-agent therapy that includes Docetaxel.
A recurrent disease that appears in a period longer than 12 months after the last dose is considered platinum sensitive. In these women, a combined chemotherapy of a platinum compound with Gemcitabine, Bevacizumab or Doxorubicin may improve their survival.
Usually, EOC late stages are characterized by metastatic tumors in the peritoneal cavity. In women with advanced disease, use of IP (Intraperitoneal) chemotherapy results in higher concentrations of the drug in the metastatic tumors, allowing some survival benefits when compared to IV (Intravenous) administration.
Over the last decade, a shift towards neoadjuvant therapy in various types of cancer, including breast cancer, has shown a decrease in morbidity and mortality.
Neoadjuvant therapy is given to the patients before primary treatment in order to downstage the tumors.
Neoadjuvant therapy has been shown to enhance clinical response rates reducing post-surgery morbidity and mortality, in 3 – year follow-up studies.
Administration of DIG790 as neoadjuvant IP therapy may improve surgical options, by reducting tumor size which will result in less extensive surgery for the tumor removal.
DiaGyn has developed an innovative nanoparticle based anticancer treatment, DIG790.
This novel carrier is loaded with an Active Pharmaceutical Ingredient Docetaxel, and includes a capping mechanism which is dependent on levels of the enzyme β-Galactosidase, widely found in cancer cells but not in normal ovary cells.